Sign In
Buy CRMD
$8.23
+0.0600 (+0.734%)
At Close: Jun 03, 2026
CorMedix Inc. Announces Regulatory and Manufacturing Updates
08:05pm, Monday, 08'th Aug 2022 GlobeNewswire Inc.
BERKELEY HEIGHTS, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention
CorMedix to Participate at the JMP Securities Life Sciences Conference
12:30pm, Wednesday, 08'th Jun 2022 GlobeNewswire Inc.
BERKELEY HEIGHTS, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention
CorMedix Inc Common Stock (CRMD) Q1 2022 Earnings Call Transcript
04:00am, Friday, 13'th May 2022 The Motley Fool
CRMD earnings call for the period ending March 31, 2022.
CorMedix (CRMD) Reports Q1 Loss, Lags Revenue Estimates
09:25pm, Thursday, 12'th May 2022 Zacks Investment Research
CorMedix (CRMD) delivered earnings and revenue surprises of 21.74% and 84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CorMedix Inc. (CRMD) CEO Joe Todisco on Q1 2022 Results - Earnings Call Transcript
08:45pm, Thursday, 12'th May 2022
CorMedix Inc. (NASDAQ:CRMD ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Daniel Ferry - Investor Relations Joe Todisco - Chief Executive Officer Matt David - Executiv
CorMedix (CRMD) Reports Q1 Loss, Lags Revenue Estimates
06:48pm, Thursday, 12'th May 2022
CorMedix (CRMD) delivered earnings and revenue surprises of 21.74% and 84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CorMedix Inc. Announces Leadership Updates and Operational Changes
12:30pm, Thursday, 12'th May 2022 GlobeNewswire Inc.
BERKELEY HEIGHTS, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention a
Adma Biologics (ADMA) Reports Q1 Loss, Tops Revenue Estimates
09:45pm, Wednesday, 11'th May 2022 Zacks Investment Research
Adma Biologics (ADMA) delivered earnings and revenue surprises of -25% and 9.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Tops Revenue Estimates
11:15am, Tuesday, 10'th May 2022 Zacks Investment Research
IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of 12.20% and 33.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stoc
Cytokinetics (CYTK) Reports Q1 Loss, Misses Revenue Estimates
09:15pm, Wednesday, 04'th May 2022 Zacks Investment Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -9.68% and 77.53%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CorMedix Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12
12:30pm, Tuesday, 03'rd May 2022 GlobeNewswire Inc.
BERKELEY HEIGHTS, N.J. , May 03, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention
Inhibrx, Inc. (INBX) Soars 15%: Is Further Upside Left in the Stock?
10:32am, Tuesday, 03'rd May 2022 Zacks Investment Research
Inhibrx, Inc. (INBX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increa
CorMedix Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12
08:30am, Tuesday, 03'rd May 2022
BERKELEY HEIGHTS, N.J. , May 03, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention an
CorMedix Inc. to Present at the 21st Annual Needham Virtual Healthcare Conference
08:30am, Monday, 04'th Apr 2022
BERKELEY HEIGHTS, N.J., April 04, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention a
CorMedix Inc Common Stock (CRMD) Q4 2021 Earnings Call Transcript
01:30am, Wednesday, 30'th Mar 2022 The Motley Fool
CRMD earnings call for the period ending December 31, 2021.
